Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (often referred to as NW Bio) is a pioneering biotechnology company headquartered in the United States, with significant operational activities in the field of cancer immunotherapy. Founded in 2001, the company has made notable strides in developing innovative therapies, particularly its lead product, DCVax®-L, which is designed to treat various types of cancer by harnessing the body’s immune system.
With a focus on personalised medicine, Northwest Biotherapeutics stands out in the biopharmaceutical industry for its unique approach to dendritic cell therapy. The company has achieved key milestones, including successful clinical trials that underscore its commitment to advancing cancer treatment. As a leader in the immunotherapy sector, NW Bio continues to position itself at the forefront of cancer research, aiming to improve patient outcomes and redefine therapeutic standards.
-21 vs industry average
Northwest Biotherapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Northwest Biotherapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Northwest Biotherapeutics, Inc. yet.
Northwest Biotherapeutics, Inc.'s reported carbon emissions
Northwest Biotherapeutics, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report any specific reduction targets or initiatives. The company has not disclosed any commitments to climate pledges or frameworks such as the Science Based Targets initiative (SBTi). As a result, there are no specific figures or scopes of emissions (Scope 1, 2, or 3) to report.
In the absence of concrete emissions data or reduction commitments, it is unclear how Northwest Biotherapeutics is addressing climate change or its carbon footprint. The company may need to enhance its transparency and engagement in climate-related initiatives to align with industry standards and expectations.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Northwest Biotherapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Northwest Biotherapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Northwest Biotherapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project